Liang, Yingjian <br/><br/>
Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.  [electronic resource] 

 -  Hepatology (Baltimore, Md.)  May 2013 
 - 1847-57 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-3350 
<br/><br/><label>Standard No.: </label>10.1002/hep.26224  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Benzylidene Compounds--pharmacology<br/>Carcinoma, Hepatocellular--drug therapy<br/>Cell Line, Tumor<br/>Cell Movement--drug effects<br/>Cell Survival--drug effects<br/>Drug Resistance, Neoplasm--drug effects<br/>Drug Therapy, Combination<br/>Humans<br/>Hypoxia--physiopathology<br/>Hypoxia-Inducible Factor 1, alpha Subunit--antagonists & inhibitors<br/>Liver Neoplasms--drug therapy<br/>Male<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>NF-kappa B--metabolism<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds--pharmacology<br/>Piperidones--pharmacology<br/>Sorafenib<br/>Treatment Outcome<br/>Von Hippel-Lindau Tumor Suppressor Protein--metabolism<br/>Xenograft Model Antitumor Assays